	US 12,071,488 B2
	Method of sensitizing cancer cells to anti-cancer treatment
Yoram Devary, Jerusalem (IL)
Assigned to TWO TO BIOTECH LTD., Jerusalem (IL)
Appl. No. 16/613,615
Filed by TWO TO BIOTECH LTD., Jerusalem (IL)
PCT Filed May 17, 2018, PCT No. PCT/IL2018/050542 § 371(c)(1), (2) Date Nov. 14, 2019, PCT Pub. No. WO2018/211514, PCT Pub. Date Nov. 22, 2018.
Claims priority of provisional application 62/507,939, filed on May 18, 2017.
Prior Publication US 2020/0115413 A1, Apr. 16, 2020
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C07K 7/08 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01)]

4 Claims

1. A method for treatment of triple negative breast cancer (TNBC) in a patient in need thereof, said method comprising administering to said patient an isolated polypeptide consisting of the amino acid sequence denoted by SEQ ID NO: 1 and an anti-cancer agent drug selected from the group consisting of doxorubicin and cisplatin.